Comparative cardiopulmonary effects of carfentanil-xylazine and medetomidine-ketamine used for immobilization of mule deer and mule deer/white-tailed deer hybrids.
Three mule deer and 4 mule deer/white-tailed deer hybrids were immobilized in a crossover study with carfentanil (10 microg/kg) + xylazine (0.3 mg/kg) (CX), and medetomidine (100 microg/kg) + ketamine (2.5 mg/kg) (MK). The deer were maintained in left lateral recumbency for 1 h with each combination. Deer were immobilized with MK in 230+/-68 s (mean +/- SD) and with CX in 282+/-83 seconds. Systolic, mean and diastolic arterial pressure were significantly higher with MK. Heart rate, PaO2, PaCO2, pH, and base excess were not significantly different between treatments. Base excess and pH increased significantly over time with both treatments. Both treatments produced hypoventilation (PaCO2 > 50 mm Hg) and hypoxemia (PaO2 < 60 mm Hg). PaO2 increased significantly over time with CX. Body temperature was significantly (P<0.05) higher with CX compared to MK. Ventricular premature contractions, atrial premature contractions, and a junctional escape rhythm were noted during CX immobilization. No arrhythmias were noted during MK immobilization. Quality of immobilization was superior with MK, with no observed movement present for the 60 min of immobilization. Movement of the head and limbs occurred in 4 animals immobilized with CX. The major complication observed with both of these treatments was hypoxemia, and supplemental inspired oxygen is recommended during immobilization. Hyperthermia can further complicate immobilization with CX, reinforcing the need for supplemental oxygen.
Caulkett
N A
NA
Department of Veterinary Anesthesiology, Radiology and Surgery, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, caulkett@admin3.usask.ca
Cribb
P H
PH
Haigh
J C
JC
D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000778:Anesthetics, Dissociative / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000827:Animal Welfare; D000818:Animals; D000835:Animals, Wild; D003670:Deer; D005283:Fentanyl / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D005334:Fever / Q000139:chemically induced / Q000662:veterinary; D006339:Heart Rate / Q000187:drug effects; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000494:pharmacology*; D000860:Hypoxia / Q000139:chemically induced / Q000662:veterinary; D007103:Immobilization; D007649:Ketamine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D020926:Medetomidine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D012119:Respiration / Q000187:drug effects; D014991:Xylazine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D000316:Adrenergic alpha-Agonists; D000701:Analgesics, Opioid; D000778:Anesthetics, Dissociative; D006993:Hypnotics and Sedatives; D014991:Xylazine; D007649:Ketamine; C017114:carfentanil; D020926:Medetomidine; D005283:Fentanyl